Novo Nordisk’s trial to treat Alzheimer’s with its GLP-1 drug failed, leading to a four-year low in its stock price. The company has been losing market share to Eli Lilly, which has dominated the GLP-1 drug market. Novo Nordisk also lost a bidding war for a promising start-up, highlighting the company’s challenges in 2025. The global GLP-1 market is projected to grow significantly, but Novo Nordisk faces stiff competition in this space. Despite setbacks, Novo Nordisk is not yet out of the race for a share of the GLP-1 market. Investors are advised to consider all factors before investing in Novo Nordisk.

Read more at Nasdaq: Why Novo Nordisk Stock Just Hit a 4-Year Low